Your search for: 'author:("Dhuyvetter, Deborah")' has returned 2 results. (0.006s) Save search

Authors: Borghys, Herman | Jacobs, Tom | Van Broeck, Bianca | Dillen, Lieve | Dhuyvetter, Deborah | Gijsen, Harrie | Mercken, Marc

Article Type: Research Article

Abstract: Beta-secretase is the first cleavage enzyme of amyloid-β protein precursor (AβPP) in the amyloidogenic pathway, leading to the formation of the plaque forming Amyloid-β (Aβ)1-42 peptide. BACE (beta-site AβPP cleaving enzyme) 1 inhibition is therefore considered to be a promising disease modifying therapy for Alzheimer's disease. An early assessment of the in vivo activity of BACE inhibitors was done in dogs since AβPP processing is the same as in humans and this species easily enables longitudinal cerebrospinal fluid (CSF) sampling. Aβ changes in CSF compared to baseline are used to evaluate target engagement of the compounds. Levels of Aβ1-37 , …Aβ1-38 , Aβ1-40 , and Aβ1-42 in CSF are measured with immunoassay (Mesoscale electrochemiluminescence technology) and with an ultra high-performance liquid chromatography mass spectrometry (UPLC-MS/MS). Two experimental BACE inhibitors were evaluated. With the immunoassay, a dose dependent decrease is observed for all four Aβ peptides. Measurements with the UPLC-MS/MS are in line with the immunoassay for Aβ1-37 , Aβ1-38 , and Aβ1-40 , however, for Aβ1-42 , differences are sometimes observed when comparing to changes seen in the other peptides with UPLC-MS/MS and with immunoassay results. Generally lower concentrations are measured with immunoassay. The reason for these differences is still unknown. Aβ1-42 is more prone to form aggregates compared to the other peptides. One hypothesis could be that while the immunoassay only measures free Aβ, bound and aggregated Aβ peptides are at least partially dissolved with the UPLC-MS/MS method, since acetonitrile is added to the CSF samples. This increases variability in the concentration of Aβ peptide measured with UPLC-MS/MS, especially for Aβ1-42 , potentially masking the compound effect on Aβ1-42 levels. Show more

Keywords: Alzheimer's disease, amyloid-β peptides, β-secretase, cerebrospinal fluid, dog

DOI: 10.3233/JAD-130599

Citation: Journal of Alzheimer's Disease, vol. 38, no. 1, pp. 39-48, 2014

Authors: Borghys, Herman | Van Broeck, Bianca | Dhuyvetter, Deborah | Jacobs, Tom | de Waepenaert, Katja | Erkens, Tim | Brooks, Melissa | Thevarkunnel, Sandy | Araujo, Joseph A.

Article Type: Research Article

Abstract: Understanding differences in Alzheimer’s disease biomarkers before the pathology becomes evident can contribute to an improved understanding of disease pathogenesis and treatment. A decrease in amyloid-β (Aβ)42 in cerebrospinal fluid (CSF) is suggested to be a biomarker for Aβ deposition in brain. However, the relevance of CSF Aβ levels prior to deposition is not entirely known. Dogs are similar to man with respect to amyloid-β protein precursor (AβPP)-processing, age-related amyloid plaque deposition, and cognitive dysfunction. In the current study, we evaluated the relation between CSF Aβ42 levels and cognitive performance in young to middle-aged dogs (1.5–7 years old). Additionally, CSF …sAβPPα and sAβPPβ were measured to evaluate AβPP processing, and CSF cytokines were measured to determine the immune status of the brain. We identified two groups of dogs showing consistently low or high CSF Aβ42 levels. Based on prior studies, it was assumed that at this age no cerebral amyloid plaques were likely to be present. The cognitive performance was evaluated in standard cognition tests. Low or high Aβ concentrations coincided with low or high sAβPPα, sAβPPβ, and CXCL-1 levels, respectively. Dogs with high Aβ concentrations showed significant learning impairments on delayed non-match to position (DNMP), object discrimination, and reversal learning compared to dogs with low Aβ concentrations. Our data support the hypothesis that high levels of CSF Aβ in dogs coincide with lower cognitive performance prior to amyloid deposition. Further experiments are needed to investigate this link, as well as the relevance with respect to Alzheimer’s disease pathology progression. Show more

Keywords: Alzheimer’s disease, amyloid-β peptides, biomarker, cognition, dog

DOI: 10.3233/JAD-160434

Citation: Journal of Alzheimer's Disease, vol. 56, no. 2, pp. 763-774, 2017